600285 羚锐制药
已收盘 12-26 15:00:00
资讯
新帖
简况
羚锐制药（600285）披露大股东部分股份解除质押，11月21日股价下跌1.38%
证券之星 · 11-21
羚锐制药（600285）披露大股东部分股份解除质押，11月21日股价下跌1.38%
羚锐制药（600285）披露取消监事会并修订公司章程议案获通过，11月18日股价上涨0.27%
证券之星 · 11-18
羚锐制药（600285）披露取消监事会并修订公司章程议案获通过，11月18日股价上涨0.27%
每周股票复盘：羚锐制药（600285）将召开2025年第三季度业绩说明会
证券之星 · 11-16
每周股票复盘：羚锐制药（600285）将召开2025年第三季度业绩说明会
每周股票复盘：羚锐制药（600285）股东户数增25.64%，净利升13.43%
证券之星 · 11-02
每周股票复盘：羚锐制药（600285）股东户数增25.64%，净利升13.43%
羚锐制药新注册《羚锐制药自动包装机物料智能识别系统软件V2.0》项目的软件著作权
证券之星 · 10-31
羚锐制药新注册《羚锐制药自动包装机物料智能识别系统软件V2.0》项目的软件著作权
羚锐制药(600285)9月30日股东户数4.25万户，较上期增加25.64%
证券之星 · 10-30
羚锐制药(600285)9月30日股东户数4.25万户，较上期增加25.64%
图解羚锐制药三季报：第三季度单季净利润同比增长9.77%
证券之星 · 10-29
图解羚锐制药三季报：第三季度单季净利润同比增长9.77%
羚锐制药（600285）股东河南羚锐集团有限公司质押480万股，占总股本0.85%
证券之星 · 09-25
羚锐制药（600285）股东河南羚锐集团有限公司质押480万股，占总股本0.85%
每周股票复盘：羚锐制药（600285）董事陈燕拟减持不超20万股
证券之星 · 09-21
每周股票复盘：羚锐制药（600285）董事陈燕拟减持不超20万股
羚锐制药最新公告：董事陈燕拟减持不超过20万股
证券之星 · 09-15
羚锐制药最新公告：董事陈燕拟减持不超过20万股
每周股票复盘：羚锐制药（600285）股东户数减少，业绩稳步增长
证券之星 · 08-24
每周股票复盘：羚锐制药（600285）股东户数减少，业绩稳步增长
羚锐制药（600285）2025年中报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 08-21
羚锐制药（600285）2025年中报简析：营收净利润同比双双增长，盈利能力上升
国金证券-羚锐制药-600285-银谷整合推进中，业绩持续稳健增长-250819
市场资讯 · 08-20
国金证券-羚锐制药-600285-银谷整合推进中，业绩持续稳健增长-250819
羚锐制药(600285.SH)发布上半年业绩，归母净利润4.74亿元，同比增长14.85%
智通财经 · 08-19
羚锐制药(600285.SH)发布上半年业绩，归母净利润4.74亿元，同比增长14.85%
中证医药卫生红利指数报16509.94点，前十大权重包含明德生物等
金融界 · 07-31
中证医药卫生红利指数报16509.94点，前十大权重包含明德生物等
华创医药投资观点&研究专题周周谈第134期：中药企业的创新布局
华创证券 · 07-12
华创医药投资观点&研究专题周周谈第134期：中药企业的创新布局
羚锐制药荣登“2024年度中国医药工业主营业务收入前100位企业”榜
中国日报网 · 07-07
羚锐制药荣登“2024年度中国医药工业主营业务收入前100位企业”榜
羚锐制药获得发明专利授权：“一种非甾体抗炎药透皮贴剂及其制备工艺”
证券之星企业动态 · 07-05
羚锐制药获得发明专利授权：“一种非甾体抗炎药透皮贴剂及其制备工艺”
个股概念调整|羚锐制药新增“创新药”概念
市场透视 · 07-04
个股概念调整|羚锐制药新增“创新药”概念
羚锐制药涨5.01% 产品创新获政策利好资金追捧
智选洞察 · 07-03
羚锐制药涨5.01% 产品创新获政策利好资金追捧
加载更多
公司概况
公司名称：
河南羚锐制药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
河南羚锐制药股份有限公司的主营业务是药品的研发、生产及销售。公司的主要产品是贴剂、片剂、胶囊剂、软膏剂。
发行价格：
8.30
{"stockData":{"symbol":"600285","market":"SH","secType":"STK","nameCN":"羚锐制药","latestPrice":20.99,"timestamp":1766732401000,"preClose":21.1,"halted":0,"volume":3557700,"delay":0,"changeRate":-0.0052,"floatShares":566000000,"shares":567000000,"eps":1.41,"marketStatus":"已收盘","change":-0.11,"latestTime":"12-26 15:00:00","open":21.13,"high":21.15,"low":20.96,"amount":74906900,"amplitude":0.009,"askPrice":20.99,"askSize":20,"bidPrice":20.98,"bidSize":350,"shortable":0,"etf":0,"ttmEps":1.41,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766971800000},"marketStatusCode":5,"adr":0,"adjPreClose":21.1,"symbolType":"stock","openAndCloseTimeList":[[1766712600000,1766719800000],[1766725200000,1766732400000]],"highLimit":23.21,"lowLimit":18.99,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":567115486,"isCdr":false,"pbRate":3.66,"roa":"--","peRate":14.886525,"roe":"20.4%","epsLYR":1.287,"committee":0.73369,"marketValue":11904000000,"turnoverRate":0.0063,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-12-29。","floatMarketCap":11878000000},"requestUrl":"/m/hq/s/600285","defaultTab":"news","newsList":[{"id":"2585499941","title":"羚锐制药（600285）披露大股东部分股份解除质押，11月21日股价下跌1.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585499941","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585499941?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:32","pubTimestamp":1763735522,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，羚锐制药报收于22.14元，较前一交易日下跌1.38%，最新总市值为125.56亿元。该股当日开盘22.4元，最高22.54元，最低22.12元，成交额达1.29亿元，换手率为1.02%。公司近日发布公告称，河南羚锐集团有限公司持有羚锐制药121,817,898股，占公司总股本的21.48%。羚锐集团本次解除质押的股份暂无后续质押计划。截至公告日，羚锐集团及其一致行动人合计持股127,813,609股，累计质押28,350,000股，占合计持股总数的22.18%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100040340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","600285","BK0070","BK0239"],"gpt_icon":0},{"id":"2584955561","title":"羚锐制药（600285）披露取消监事会并修订公司章程议案获通过，11月18日股价上涨0.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584955561","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584955561?lang=zh_cn&edition=full","pubTime":"2025-11-18 22:26","pubTimestamp":1763475985,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘，羚锐制药报收于22.26元，较前一交易日上涨0.27%，最新总市值为126.24亿元。公司近日发布公告称，河南羚锐制药股份有限公司于2025年11月18日召开2025年第一次临时股东大会，会议由董事长熊伟主持，采用现场与网络投票相结合方式召开，审议通过了关于取消监事会并修订《公司章程》的议案，以及多项公司治理制度修订议案，包括《股东会议事规则》《董事会议事规则》《独立董事工作制度》等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800039967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285","BK0188","BK0070","BK0077","BK0239"],"gpt_icon":0},{"id":"2583546686","title":"每周股票复盘：羚锐制药（600285）将召开2025年第三季度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2583546686","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583546686?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:42","pubTimestamp":1763239332,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，羚锐制药报收于22.68元，较上周的22.6元上涨0.35%。本周，羚锐制药11月12日盘中最高价报23.38元。羚锐制药当前最新总市值128.62亿元，在中药板块市值排名17/67，在两市A股市值排名1492/5165。本周关注点公司公告汇总：羚锐制药将于2025年11月19日召开第三季度业绩说明会，介绍经营成果并回应投资者提问。投资者可于2025年11月12日至11月18日16:00前通过上证路演中心或公司邮箱600285@lingrui.com提前提问。说明会结束后可通过该平台查看会议内容。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0077","BK0070","600285"],"gpt_icon":0},{"id":"2580749934","title":"每周股票复盘：羚锐制药（600285）股东户数增25.64%，净利升13.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580749934","media":"证券之星","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580749934?lang=zh_cn&edition=full","pubTime":"2025-11-02 05:54","pubTimestamp":1762034056,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，羚锐制药报收于22.68元，较上周的23.08元下跌1.73%。本周，羚锐制药10月28日盘中最高价报23.5元。业绩披露要点：2025年前三季度归母净利润6.51亿元，同比上升13.43%。股本股东变化截至2025年9月30日，公司股东户数为4.25万户，较6月30日增加8679户，增幅25.64%。第三季度单季度主营收入9.42亿元，同比上升10.44%；归母净利润1.77亿元，同比上升9.77%；扣非净利润1.63亿元，同比上升10.41%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285","BK0070","BK0239","BK0077","BK0188"],"gpt_icon":0},{"id":"2579552173","title":"羚锐制药新注册《羚锐制药自动包装机物料智能识别系统软件V2.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2579552173","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579552173?lang=zh_cn&edition=full","pubTime":"2025-10-31 02:04","pubTimestamp":1761847465,"startTime":"0","endTime":"0","summary":"证券之星消息，近日羚锐制药新注册了《羚锐制药自动包装机物料智能识别系统软件V2.0》项目的软件著作权。今年以来羚锐制药新注册软件著作权2个。结合公司2025年中报财务数据，今年上半年公司在研发方面投入了6306.09万元，同比增33.63%。通过天眼查大数据分析，河南羚锐制药股份有限公司共对外投资了14家企业，参与招投标项目26057次；财产线索方面有商标信息381条，专利信息250条，著作权信息40条；此外企业还拥有行政许可355个。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100002732.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","600285","BK0070","BK0239"],"gpt_icon":0},{"id":"2579824190","title":"羚锐制药(600285)9月30日股东户数4.25万户，较上期增加25.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579824190","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579824190?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:13","pubTimestamp":1761815619,"startTime":"0","endTime":"0","summary":"证券之星消息，近日羚锐制药披露，截至2025年9月30日公司股东户数为4.25万户，较6月30日增加8679.0户，增幅为25.64%。在中药行业个股中，羚锐制药股东户数低于行业平均水平，截至9月30日，中药行业平均股东户数为5.35万户。从股价来看，2025年6月30日至2025年9月30日，羚锐制药区间跌幅为3.31%，在此期间股东户数增加8679.0户，增幅为25.64%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000031873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0070","BK0239","600285","BK0188"],"gpt_icon":0},{"id":"2579707959","title":"图解羚锐制药三季报：第三季度单季净利润同比增长9.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579707959","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579707959?lang=zh_cn&edition=full","pubTime":"2025-10-29 19:47","pubTimestamp":1761738424,"startTime":"0","endTime":"0","summary":"证券之星消息，羚锐制药2025年三季报显示，前三季度公司主营收入30.41亿元，同比上升10.23%；归母净利润6.51亿元，同比上升13.43%；扣非净利润6.05亿元，同比上升11.77%；其中2025年第三季度，公司单季度主营收入9.42亿元，同比上升10.44%；单季度归母净利润1.77亿元，同比上升9.77%；单季度扣非净利润1.63亿元，同比上升10.41%；负债率42.96%，投资收益3672.74万元，财务费用-511.25万元，毛利率81.02%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900040560.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285"],"gpt_icon":0},{"id":"2570954780","title":"羚锐制药（600285）股东河南羚锐集团有限公司质押480万股，占总股本0.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2570954780","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570954780?lang=zh_cn&edition=full","pubTime":"2025-09-25 18:26","pubTimestamp":1758795993,"startTime":"0","endTime":"0","summary":"证券之星消息，羚锐制药9月25日公开信息显示，股东河南羚锐集团有限公司向中信银行股份有限公司信阳分行合计质押480.0万股，占总股本0.85%。质押详情见下表：截止本公告日，股东河南羚锐集团有限公司已累计质押股份3173.0万股，占其持股总数的26.05%。羚锐制药主营业务：药品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092500028864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0070","600285","BK0239","BK0188"],"gpt_icon":0},{"id":"2569249359","title":"每周股票复盘：羚锐制药（600285）董事陈燕拟减持不超20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2569249359","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569249359?lang=zh_cn&edition=full","pubTime":"2025-09-21 05:07","pubTimestamp":1758402434,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘，羚锐制药报收于22.3元，较上周的22.83元下跌2.32%。本周，羚锐制药9月15日盘中最高价报22.94元。公司公告汇总羚锐制药董事、副总经理陈燕女士因个人资金需求，拟自公告披露之日起15个交易日后的3个月内，通过集中竞价交易方式减持公司股份不超过200,000股，占公司总股本不超过0.0353%，不超过其所持股份的25%。陈燕女士当前持有公司股份965,000股，占总股本0.17%，股份来源为股权激励所得。减持将遵守相关法律法规并履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092100001326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600285","BK0188","BK0070","BK0077"],"gpt_icon":0},{"id":"2567194154","title":"羚锐制药最新公告：董事陈燕拟减持不超过20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2567194154","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567194154?lang=zh_cn&edition=full","pubTime":"2025-09-15 16:32","pubTimestamp":1757925169,"startTime":"0","endTime":"0","summary":"羚锐制药(600285.SH)公告称，公司董事、副总经理陈燕因个人资金需求，计划通过集中竞价交易方式减持不超过20万股公司股票，占公司总股本的0.0353%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091500020809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0070","BK0077","BK0239","600285"],"gpt_icon":0},{"id":"2561253460","title":"每周股票复盘：羚锐制药（600285）股东户数减少，业绩稳步增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2561253460","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561253460?lang=zh_cn&edition=full","pubTime":"2025-08-24 06:19","pubTimestamp":1755987546,"startTime":"0","endTime":"0","summary":"截至2025年8月22日收盘，羚锐制药报收于24.12元，较上周的22.83元上涨5.65%。本周，羚锐制药8月21日盘中最高价报24.75元。本周关注点股本股东变化：截至2025年6月30日，羚锐制药股东户数减少2445户，减幅为6.74%业绩披露要点：羚锐制药2025年中报显示，公司主营收入20.99亿元，同比上升10.14%股本股东变化近日羚锐制药披露，截至2025年6月30日公司股东户数为3.38万户，较3月31日减少2445.0户，减幅为6.74%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082400001820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","600285","BK0070","BK0188"],"gpt_icon":0},{"id":"2561648220","title":"羚锐制药（600285）2025年中报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2561648220","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561648220?lang=zh_cn&edition=full","pubTime":"2025-08-21 06:02","pubTimestamp":1755727367,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期羚锐制药发布2025年中报。截至本报告期末，公司营业总收入20.99亿元，同比上升10.14%，归母净利润4.74亿元，同比上升14.85%。按单季度数据看，第二季度营业总收入10.78亿元，同比上升8.17%，第二季度归母净利润2.58亿元，同比上升15.68%。本报告期羚锐制药盈利能力上升，毛利率同比增幅6.95%，净利率同比增幅4.59%。应交税费变动幅度为66.42%,原因:应交增值税及企业所得税增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082100002557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285"],"gpt_icon":0},{"id":"2560146638","title":"国金证券-羚锐制药-600285-银谷整合推进中，业绩持续稳健增长-250819","url":"https://stock-news.laohu8.com/highlight/detail?id=2560146638","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560146638?lang=zh_cn&edition=full","pubTime":"2025-08-20 07:39","pubTimestamp":1755646740,"startTime":"0","endTime":"0","summary":"公司上半年完成对银谷制药90%股权的收购，目前在推进双方的协同发展。银谷制药并表后，实现营业收入约0.99亿元，净利润约0.13亿元，有望形成公司第二增长曲线，为公司未来稳健增长增添新动能。2025年7月1日，公司发布公告，苯环喹溴铵鼻喷雾剂新增适应症获批，用于改善感冒引起的流涕、鼻塞等症状，将进一步拓宽治疗领域，提升产品竞争力。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-08-20/doc-infmqrup7050912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0012","600285","BK0183","BK0077","BK0188","BK0239","BK0028","BK0070","BK0201","600109","BK0276"],"gpt_icon":0},{"id":"2560642162","title":"羚锐制药(600285.SH)发布上半年业绩，归母净利润4.74亿元，同比增长14.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2560642162","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560642162?lang=zh_cn&edition=full","pubTime":"2025-08-19 17:38","pubTimestamp":1755596302,"startTime":"0","endTime":"0","summary":"智通财经APP讯，羚锐制药(600285.SH)发布2025年半年度报告，报告期内，公司实现营业收入20.99亿元，同比增长10.14%。实现归属于上市公司股东的净利润4.74亿元，同比增长14.85%。实现归属于上市公司股东的扣除非经常性损益的净利润4.42亿元，同比增长12.28%。基本每股收益0.836元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1331565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"羚锐制药(600285.SH)发布上半年业绩，归母净利润4.74亿元，同比增长14.85%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600285"],"gpt_icon":0},{"id":"2555888141","title":"中证医药卫生红利指数报16509.94点，前十大权重包含明德生物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2555888141","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555888141?lang=zh_cn&edition=full","pubTime":"2025-07-31 16:19","pubTimestamp":1753949998,"startTime":"0","endTime":"0","summary":"金融界7月31日消息，上证指数低开低走，中证医药卫生红利指数 报16509.94点。数据统计显示，中证医药卫生红利指数近一个月上涨12.87%，近三个月上涨19.55%，年至今上涨13.27%。从中证医药卫生红利指数持仓的市场板块来看，上海证券交易所占比50.82%、深圳证券交易所占比49.18%。从中证医药卫生红利指数持仓样本的行业来看，中药占比34.45%、化学药占比25.27%、医疗商业与服务占比16.54%、医疗器械占比13.84%、生物药品占比7.89%、制药与生物科技服务占比2.01%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507311637239729a8ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507311637239729a8ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","000933.SH","000015.SH","399933","BK0077","BK0070","603367","002932","600285","600479","BK0188","600329","688658"],"gpt_icon":0},{"id":"2550299546","title":"华创医药投资观点&研究专题周周谈第134期：中药企业的创新布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2550299546","media":"华创证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550299546?lang=zh_cn&edition=full","pubTime":"2025-07-12 00:00","pubTimestamp":1752249600,"startTime":"0","endTime":"0","summary":"本周，中信医药指数上涨1.80%，跑赢沪深300指数0.98个百分点，在中信30个一级行业中排名第16位。本周涨幅前十名股票为前沿生物-U、美迪西、联环药业、康辰药业、启迪药业、华纳药厂、浩欧博、塞力医疗、福瑞股份、广生堂。本周跌幅前十名股票ST未名、神州细胞、舒泰神、一品红、海辰药业、华海药业、美诺华、永安药业、荣昌生物、创新医疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712112220a445eec5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712112220a445eec5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600285","600351","600518","600594","603896","600080","600129","605199","600479","BK0239","603139","600535","600671","600222","603567","159377","603998","600993","600750","600252","600771","399275","600976","600566","600332","603439","603858","600557","600572","600436"],"gpt_icon":0},{"id":"2549309234","title":"羚锐制药荣登“2024年度中国医药工业主营业务收入前100位企业”榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2549309234","media":"中国日报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549309234?lang=zh_cn&edition=full","pubTime":"2025-07-07 11:45","pubTimestamp":1751859908,"startTime":"0","endTime":"0","summary":"7月6日，备受瞩目的第42届全国医药工业信息年会在北京昌平举行，会上发布了“2024年度中国医药工业主营业务收入前100位企业”榜，羚锐制药凭借稳健的经营业绩荣登榜单第94位。羚锐制药2024年度排名较2023年度稳步提升，这一历程清晰印证了羚锐制药在战略引领、创新驱动、精益管理和市场开拓等方面取得的扎实成效，是企业综合竞争力持续增强的有力体现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707114741a43aef90&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707114741a43aef90&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0175","BK0082","BK0185","600056","BK0028","BK0077","600285","BK0070","BK0188","BK0010","BK0239","BK0250"],"gpt_icon":0},{"id":"2549318240","title":"羚锐制药获得发明专利授权：“一种非甾体抗炎药透皮贴剂及其制备工艺”","url":"https://stock-news.laohu8.com/highlight/detail?id=2549318240","media":"证券之星企业动态","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549318240?lang=zh_cn&edition=full","pubTime":"2025-07-05 02:46","pubTimestamp":1751654815,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示羚锐制药新获得一项发明专利授权，专利名为“一种非甾体抗炎药透皮贴剂及其制备工艺”，专利申请号为CN202310709841.9，授权日为2025年7月4日。本发明所述非甾体抗炎药透皮贴剂具有透气性，粘附力适中，无皮肤刺激性，可局部给药，经皮透过量高，残药量低，有助于提高药物的生物利用度及疗效，减少了给药次数及给药量。今年以来羚锐制药新获得专利授权5个，较去年同期减少了16.67%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250705025744979a3e00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250705025744979a3e00&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600285","BK0239","BK0188","BK0070","BK0077"],"gpt_icon":0},{"id":"2548357107","title":"个股概念调整|羚锐制药新增“创新药”概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2548357107","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548357107?lang=zh_cn&edition=full","pubTime":"2025-07-04 15:15","pubTimestamp":1751613308,"startTime":"0","endTime":"0","summary":"2025年07月04日，羚锐制药新增了创新药概念。羚锐制药的所属概念，还有：社保重仓、融资融券、丹参概念、何首乌概念、红花概念、黄芪概念、转融券标的、养老金持股、股份回购、标普道琼斯中国、中成药。个股概念调整既是市场认知的再校准，也是企业战略的显性化映射。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704151513a4cee4b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704151513a4cee4b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0077","600285","BK0070","BK0239","159992"],"gpt_icon":0},{"id":"2548195847","title":"羚锐制药涨5.01% 产品创新获政策利好资金追捧","url":"https://stock-news.laohu8.com/highlight/detail?id=2548195847","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548195847?lang=zh_cn&edition=full","pubTime":"2025-07-03 09:39","pubTimestamp":1751506763,"startTime":"0","endTime":"0","summary":"羚锐制药股价今日大幅上涨，截至09点38分，最新价为24.30元/股，涨幅达5.01%。产品创新驱动资金聚焦羚锐制药子公司苯环喹溴铵鼻喷雾剂新增感冒适应症于7月1日获批，成为国内首个针对感冒鼻部症状的M受体拮抗剂鼻喷剂。截至7月2日，主力资金累计净流入2691万元，推动股价单日上涨5.08%。创新药板块近期受政策利好提振，国家医保局出台支持创新药发展措施，年内板块成交额同比增超30%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703093928a4cc2d2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703093928a4cc2d2c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0070","600285","BK0077","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766762200058,"stockEarnings":[{"period":"1week","weight":-0.0038},{"period":"1month","weight":-0.0508},{"period":"3month","weight":-0.0491},{"period":"6month","weight":-0.0701},{"period":"1year","weight":-0.0148},{"period":"ytd","weight":-0.0104}],"compareEarnings":[{"period":"1week","weight":0.0215},{"period":"1month","weight":0.0232},{"period":"3month","weight":0.0344},{"period":"6month","weight":0.1564},{"period":"1year","weight":0.1669},{"period":"ytd","weight":0.1814}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"河南羚锐制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"42522人(较上一季度增加25.64%)","perCapita":"13307股","listingDate":"2000-10-18","address":"河南省信阳市新县将军路666号","registeredCapital":"56711万元","survey":" 河南羚锐制药股份有限公司的主营业务是药品的研发、生产及销售。公司的主要产品是贴剂、片剂、胶囊剂、软膏剂。","listedPrice":8.3},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"羚锐制药(600285)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供羚锐制药(600285)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"羚锐制药,600285,羚锐制药股票,羚锐制药股票老虎,羚锐制药股票老虎国际,羚锐制药行情,羚锐制药股票行情,羚锐制药股价,羚锐制药股市,羚锐制药股票价格,羚锐制药股票交易,羚锐制药股票购买,羚锐制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"羚锐制药(600285)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供羚锐制药(600285)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}